Four critical capabilities for 2030
No one would dispute that the rules of engagement in global pharma are changing rapidly. Firstly, we see that power is re-balancing across the healthcare value chain and forcing a downward pressure on pricing. Secondly, the swing from treatment to prevention is attracting a host of new entrants, like tech start-ups, which is also challenging to incumbent global pharma.
Pharma companies of today must get ahead and anticipate these shifts, fundamentally re-imagining their businesses, operating models and capabilities to remain relevant and competitive. Through conversations with our clients and leveraging our industry expertise, we have identified four critical capabilities in order for global pharma’s to remain agile, strive toward operational excellence and we propose are critical for survival:
Embracing an outside-in approach, we look at how other sectors have adapted to similar disruption, and call People Leaders in global pharma to harness workforce shaping as a means of accessing these critical capabilities and the re-shaping of current business models.
Download the Reshaping the future of pharma (PDF 2.68MB) report to find out more.
© 2020 KPMG LLP, a UK limited liability partnership, and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative, a Swiss entity. All rights reserved.
KPMG International Cooperative (“KPMG International”) is a Swiss entity. Member firms of the KPMG network of independent firms are affiliated with KPMG International. KPMG International provides no client services. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm.